ERS publications

ERJOR: Peri-transplant CFS trajectory predicts long-term survival in ILD, underscoring frailty as a modifiable risk factor and reinforcing the need for routine assessment and targeted interventions to enhance patient outcomes across the transplant course bit.ly/4jZNVsh

ERJ Open Research: Tezepelumab treatment was associated with meaningful improvement in small airway function and better asthma control in a real-world cohort. Small airway function is an important treatable trait in severe asthma. bit.ly/4rlbuhH

Vista preliminar emocionante del artículo sobre Bendopnea @ERSpublications ☑️Dificultad para respirar al inclinarse hacia adelante común con derrame pleural ☑️Bendopnea asociada con derrame mayor, más disnea, 6MWT más corto ☑️Aquellos con bendopnea tienen mejor mejoría en 6MWT post-drenaje @tsanz_thoracic @AAB_IP @PleuralPOCUS @PulmPEEPs @ALATorax @SMNYCT @TheRACP @UCLAPCCM @iPulmOG @UKPleura @pleuralwales @NeumologiaHR

ERJOR: In patients with PH exposed to simulated ∼2500-m hypoxia, a single 50-mg sildenafil dose had no effect at rest but reduced exercise-induced pulmonary pressure and resistance, potentially improving exercise capacity during hypoxic exposure bit.ly/4rHhvFz

ERJOR: Themes of invisibility and visibility, complexity of assessment, and prioritising breathlessness in fibrotic interstitial lung disease revealed knowledge gaps, need for activity-based assessment, new tools and experiential learning for clinicians bit.ly/3NiBbAI

At this year’s #ERSCongress, we are pleased to be hosting a selection of language sessions to celebrate ERS’s global collaborations and partnerships🌍 ersnet.org/congress-and-e…

Les compartimos la nueva revisión de @erspublications sobre la hipertensión pulmonar asociada a enfermedad pulmonar intersticial (ILD-PH): Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review DOI: 10.1183/13993003.02651-2025 @EuroRespSoc

🚨 ERS members: join us at the Society’s General Assembly 2026 at this year’s Congress! Taking place on Tuesday 8 September (14:00–15:30 CEST, Room 3G, FIRA Barcelona) this meeting is an unmissable opportunity to have your say on the future of ERS. More: ersnet.org/news-and-featu…

ERJOR: European focus groups explored how patients with IPF/PPF and their caregivers define “good health”. The results show that health – from a patient perspective – links physical, emotional and social aspects, and that unfulfilled care needs remain. bit.ly/3KRBJwH

ERJ Open Research: Quality of life (QoL) is the highest prioritised outcome by children with bronchiectasis and their parents. A valid and reliable BC-QoL was developed to address this need. bit.ly/4q3xZGU

ERJ Open Research: Sinus involvement is common in bronchiectasis and adversely impacts symptoms, but not hospitalisations or mortality. Nasal polyps are independently associated with type 2 inflammation in bronchiectasis. bit.ly/4k43bED

ERJ Open Research: People with asthma report several barriers to increasing physical activity in daily life that can be overcome with appropriate behavioural intervention strategies. bit.ly/3O4cKHr

Esto refleja la complejidad de lograr identificar aquellos pacientes con mayor riesgo sin factores comunes y la problemática del screening en no fumadores. Un interrogante aun por contestar.

💡 What will be the key sessions at #ERSCough2026? And how will the event’s interactivity boost the experience of early-career delegates? Learn more here from Dr Imran Satia 👇 There is still time to join us – register: channel.ersnet.org/event-390-ers-…

ERJOR: The potent AT2 receptor agonist buloxibutid reduces the proinflammatory pathogenetic response in a model of viral infection in primary human ATII cells. Crucially, buloxibutid treatment does not alter the protective alveolar antiviral responses. bit.ly/4rYJxx4

ERJ Open Research: Genetic predisposition plays a key role in lung function decline, influencing whether individuals experience slower or accelerated deterioration bit.ly/3ZwgIuX

Rarely, chronic eosinophilic pneumonia progresses to fibrosis. Anti-IL-5/IL-5R treatment is effective as a steroid-sparing agent and has a rationale in reducing the risk of fibrosis. Antifibrotic treatment is available in progressive fibrosis patients. bit.ly/4nc8CCK

Lung function was measured in Kenya using race-neutral predictive equations. The lung function of children and adults was less than predicted. In adults, a negative association between lung function and age was greater in urban, than in rural, settings. bit.ly/4t4Sk13

91 new lung cancer risk models have been identified since 2020. Despite strong discrimination, limited validation and calibration could hinder adoption. Focus should shift to improving existing models, evaluation, cost-effectiveness and real-world impact. bit.ly/4efpbvh

ERJ Open Research: Six clusters of AATD clinical phenotypes – mainly differing in age at diagnosis, lung function and smoking, in addition to genotype – were identified using EARCO baseline data, and hold promise for therapeutic and prognostic value bit.ly/4swWLkY